Structure via PubChem · Public domain (PubChem)
GS-441524
Sign in to saveAlso known as GS441524, (2R,3S,5R)-2-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furancarbonitrile
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it), but GS-441524 has been found to be effective treatment for FIP.
Chemical data
- Formula
- C12H13N5O4
- Molecular weight
- 291.26 g/mol
- IUPAC name
- (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile
- SMILES
- C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N
- InChIKey
- BRDWIEOJOWJCLU-LTGWCKQJSA-N
- XLogP
- -1.4
- Polar surface area
- 150 Ų
- H-bond donors
- 4
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 291.09675389600005
Show 5 more facts
- chemical formula
- C₁₂H₁₃N₅O₄
- canonical SMILES
- C1=C2C(=NC=NN2C(=C1)C3(C(C(C(O3)CO)O)O)C#N)N
- isomeric SMILES
- C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N
- Commons category
- GS-441524
- subject has role
- antiviral drug
Sources (1)
via Wikidata · CC0
~8 min read
Encyclopedic overview
13 sectionsContents
- Use and research
- Feline infectious peritonitis
- COVID-19
- USA regulations
- Deuremidevir
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Mechanism of action
- Tolerance
- See also
- Notes
- References
GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it), but GS-441524 has been found to be effective treatment for FIP.
It is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use. In several countries oral GS-441524 tablets (and injectable remdesivir) became legally available to vets for the treatment of FIP in cats, for example Australia, the Netherlands, and the United Kingdom.
Excerpted from Wikipedia’s “GS-441524” article, available under the CC BY-SA 4.0 licence.